NUSAP1 promotes invasion and metastasis of prostate cancer

Gordon, Catherine A.; Gong, Xue; Ganesh, Durga; Brooks, James D.

doi:10.18632/oncotarget.15604

Cited by 63 publications

(67 citation statements)

References 61 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Okamoto et al revealed high NUSAP1 expression was related to more advanced T stage and inhibiting NUSAP1 resulted in the suppression of cell proliferation in Oral Squamous Cell Carcinoma (OSCC). Similar biological functions of NUSAP1 were also observed in other malignancies, including breast cancer, hepatocellular carcinoma (HCC), glioblastoma multiforme (GBM), colorectal cancer, astrocytoma, glioma, renal cell carcinoma, and prostate cancer . And previous studies also reported downregulating NUSAP1 could enhance the susceptibility to epirubicin in invasive breast cancer and the anti‐tumour effect of paclitaxel in OSCC .…”

Section: Introductionsupporting

confidence: 59%

Downregulation of NUSAP1 suppresses cell proliferation, migration, and invasion via inhibiting mTORC1 signalling pathway in gastric cancer

Lin

et al. 2019

Cell Biochemistry & Function

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide, and outstanding biomarkers for therapeutic targets or predicting GC survival are still lacking. Increasing evidence indicated that nucleolar and spindle associated protein 1 (NUSAP1) involved in regulating the progression of various cancers; however, its specific role in GC remained unclear. In this study, we found that NUSAP1 was upregulated in the GC tissues and cell lines via analysing data from The Cancer Genome Atlas (TCGA), gene expression omnibus (GEO), qRT-PCR, and western blot assays. Patients with high NUSAP1 expression levels showed shorter freeprogression survival (FPS), larger tumour size, and higher lymphatic metastasis rate compared with those with low NUSAP1 expression. Further functional experiments revealed knockdown of NUSAP1 could inhibit the growth, migration, and invasion of GC cells in vitro and vivo. Additionally, silencing NUSAP1 induced G0/G1 phase arrest, apoptosis, and suppressed the epithelial-mesenchymal transition (EMT) process. Finally, we performed gene set enrichment analysis (GSEA) and observed NUSAP1 was positive with mTORC1 signalling pathway, which was verified by the subsequent immunoblotting. In conclusion, our findings suggested that NUSAP1 contributed to GC progression and may act as a potential therapeutic target for GC.Significance of the study: Our results firstly illuminated that NUSAP1 expression was significantly upregulated in GC tissues and predicted poor FPS. Silencing it could attenuate GC progression via inhibiting mTORC1 signalling pathway. Hence, NUSAP1 may act as a promising therapy target for GC.

show abstract

Section: Introductionsupporting

confidence: 59%

Downregulation of NUSAP1 suppresses cell proliferation, migration, and invasion via inhibiting mTORC1 signalling pathway in gastric cancer

Lin

et al. 2019

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…NUSAP1 is a cell cycle-related protein that plays a key role in mitosis. It has been proved that NUSAP1 regulates apoptosis, proliferation, and metastasis [24]. Accumulating evidence reveals that NUSAP1 may serve as a biomarker for carcinogenesis and cancer progression [25].…”

Section: Discussionmentioning

confidence: 99%

Decreased Expression of NUSAP1 Predicts Poor Overall Survival in Cervical Cancer

Xie¹,

Ouyang²,

Zhang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Nucleolar and spindle-associated protein 1 (NUSAP1) was previously reported to be associated with poor prognosis in multiple cancers. In the present study, we comprehensively investigated the clinicopathological features and potential prognostic value of NUSAP1 in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). Methods: The expression profiles of the genes were extracted from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), Cancer Cell Line Encyclopedia (CCLE), Gene Expression Profiling Interactive Analysis (GEPIA), and The Human Protein Atlas databases. The association between clinicopathological characteristics and NUSAP1 was analyzed using logistic regression in TCGA patients and receiver operating characteristic (ROC) curve analysis for GSE7803, GSE9750, and GSE63514 datasets. The prognostic value of NUSAP1 in TCGA patients was evaluated using the Kaplan-Meier method and Cox regression. Gene set enrichment analysis (GSEA) was conducted using TCGA dataset. Results: A total of 68 differentially expressed genes (DEGs) were identified in CESC. ROC analysis of NUSAP1 suggested that the area under the ROC curve was 0.968. Kaplan-Meier survival analysis indicated that CESC with low expression of NUSAP1 has a worse prognosis than CESC with high NUSAP1 expression (P = 0.005). The logistic regression revealed that low NUSAP1 expression in CESC was related to advanced tumor stage in TCGA database. Moreover, Cox regression analysis showed that NUSAP1 expression correlated significantly with prognosis in the case of patients in TCGA database. GSEA demonstrated that CESC patients with high expression of NUSAP1 were enriched in the G2M checkpoint, MYC targets, and breast cancer ZNF217. Conclusion: The results suggest that identification of DEGs might enhance our understanding of the causes and molecular mechanisms underlying the development of CESC. Moreover, NUSAP1 may play an important role in CESC progression and prognosis and may serve as a valuable indicator of poor survival in CESC.

show abstract

“…NUSAP1 overexpression has been described in bladder, cervix, colon, glioblastoma, liver, lung, oral squamous cell carcinoma, prostrate, kidney, and breast [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] cancers. Multiple studies have correlated its over-expression with a poor prognosis [22,28,30,32,36,37,40,41]. Zhang et al [37] demonstrated that down-regulation of NUSAP1 suppressed proliferation, migration and invasion of MCF7 cells by disturbing the regulation of CDK1 and DLGAP5, and reported increased susceptibility to epirubicin [37].…”

Section: Discussionmentioning

confidence: 99%

NUSAP1 and KIAA0101 downregulation by neo-adjuvant therapy is associated with better outcome and survival in breast cancer.

Magallanes-Garza

Santuario‐Facio

Varela-Varela

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Studies of molecular changes occurring before and after neo-adjuvant chemotherapy (NCT) for breast cancer may unveil genetic biomarkers to predict therapy response. This study aimed at identifying genomic changes in breast primary tumors of patients under NCT. Gene expression changes were correlated with pathological response and survival.Methods: Gene expression profiles in tissue samples from pre and post NCT were obtained by a non-supervised classification analysis. Thirty-nine patients were classified according to their response to the chemotherapy as pathologic complete responders or non-responders (pCR and no-pCR, respectively). Overall survival was assessed by comparing gene expression values before NCT using the Log-rank (Mantel-Cox) test. Results: A signature constituted by 43 genes was obtained to stratify pCR and no-pCR patients after NCT (FC = + 3, FDR p -value < 0.0298). These genes were involved in regulation of the mitotic nuclear division and the anaphase-promoting complex-dependent catabolic process. Remarkably, over-expression of NUSAP1 and KIAA0101 were associated to poor overall survival. Conclusions: A new expression signature evaluating response for the neo-adjuvant chemotherapy stratified pathological response. The expression levels of NUSAP1 and KIAA0101 before and after the neo-adjuvant therapy may be useful to predict overall survival.

show abstract

NUSAP1 promotes invasion and metastasis of prostate cancer

Cited by 63 publications

References 61 publications

Downregulation of NUSAP1 suppresses cell proliferation, migration, and invasion via inhibiting mTORC1 signalling pathway in gastric cancer

Downregulation of NUSAP1 suppresses cell proliferation, migration, and invasion via inhibiting mTORC1 signalling pathway in gastric cancer

Decreased Expression of NUSAP1 Predicts Poor Overall Survival in Cervical Cancer

NUSAP1 and KIAA0101 downregulation by neo-adjuvant therapy is associated with better outcome and survival in breast cancer.

Contact Info

Product

Resources

About